Prothena Corporation PLC

PRTA

Add to Watchlist

9.680USD

-0.180-1.83%

Market hours （ET）Quotes delayed by 15 min

Prothena Corporation PLC's Score

Industry at a Glance

Industry Ranking

94 / 382

Overall Ranking

207 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Prothena Corporation PLC Highlights

StrengthsRisks

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.68M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.68M.

Fairly Valued

The company’s latest PE is -3.51, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 50.39M shares, decreasing 22.37% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 4.73K shares of this stock.

Analyst Rating

Based on 6 analysts

Hold

Current Rating

21.400

Target Price

+122.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Prothena Corporation PLC is 6.20, ranking 274 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 51.08M, representing a year-over-year increase of 1706.36%, while its net profit experienced a year-over-year increase of 154.36%.

Score

Industry at a Glance

Previous score

6.20

Change

0



Financials

9.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.87

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Prothena Corporation PLC is 7.12, ranking 161 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.51, which is -69.30% below the recent high of -1.08 and -1015.44% above the recent low of -39.18.

Score

Industry at a Glance

Previous score

7.12

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 94/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Prothena Corporation PLC is 6.67, ranking 324 out of 382 in the Biotechnology & Medical Research industry. The average price target is 18.50, with a high of 36.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

6.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Prothena Corporation PLC is 6.14, ranking 287 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.35 and the support level at 8.83, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.98

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Prothena Corporation PLC is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.24%, representing a quarter-over-quarter increase of 19.52%. The largest institutional shareholder is Steven Cohen, holding a total of 860.02K shares, representing 1.64% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.55M

-4.43%

Scully (William P)

5.28M

-1.31%

Fennell (Todd W.)

4.50M

+3.33%

Rubric Capital Management LP

3.68M

+138.73%

BlackRock Institutional Trust Company, N.A.

3.33M

+12.04%

State Street Investment Management (US)

2.27M

+151.69%

D. E. Shaw & Co., L.P.

1.68M

+27.82%

Armistice Capital LLC

1.50M

-17.76%

Adar1 Capital Management LLC

1.46M

-0.77%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Prothena Corporation PLC is 5.28, ranking 46 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Prothena Corporation PLC

PRTA

6.71 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.66 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment